These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
69 related articles for article (PubMed ID: 12457178)
1. Skin antibiotics get in the loop. Kopp E; Medzhitov R Nat Med; 2002 Dec; 8(12):1359-60. PubMed ID: 12457178 [No Abstract] [Full Text] [Related]
2. Immunology. Versatile defensins. Ganz T Science; 2002 Nov; 298(5595):977-9. PubMed ID: 12411693 [No Abstract] [Full Text] [Related]
3. [Innate immunity and allergic diseases]. Akira S Arerugi; 2002 Apr; 51(4):352-6. PubMed ID: 12014025 [No Abstract] [Full Text] [Related]
4. Alerting dendritic cells to pathogens: the importance of Toll-like receptor signaling of stromal cells. Colonna M Proc Natl Acad Sci U S A; 2004 Nov; 101(46):16083-4. PubMed ID: 15534204 [No Abstract] [Full Text] [Related]
5. Toll-like receptor signaling in anti-cancer immunity. Okamoto M; Sato M J Med Invest; 2003 Feb; 50(1-2):9-24. PubMed ID: 12630564 [TBL] [Abstract][Full Text] [Related]
6. Balancing life and death. Moser M Nat Immunol; 2004 Jun; 5(6):559-60. PubMed ID: 15164011 [No Abstract] [Full Text] [Related]
7. The immunobiology of the TLR9 subfamily. Wagner H Trends Immunol; 2004 Jul; 25(7):381-6. PubMed ID: 15207506 [No Abstract] [Full Text] [Related]
8. Toll pathway-dependent blockade of CD4+CD25+ T cell-mediated suppression by dendritic cells. Pasare C; Medzhitov R Science; 2003 Feb; 299(5609):1033-6. PubMed ID: 12532024 [TBL] [Abstract][Full Text] [Related]
9. Synergistic stimulation of human monocytes and dendritic cells by Toll-like receptor 4 and NOD1- and NOD2-activating agonists. Fritz JH; Girardin SE; Fitting C; Werts C; Mengin-Lecreulx D; Caroff M; Cavaillon JM; Philpott DJ; Adib-Conquy M Eur J Immunol; 2005 Aug; 35(8):2459-70. PubMed ID: 16021602 [TBL] [Abstract][Full Text] [Related]
10. Adjuvants of immunity: harnessing innate immunity to promote adaptive immunity. Bendelac A; Medzhitov R J Exp Med; 2002 Mar; 195(5):F19-23. PubMed ID: 11877490 [No Abstract] [Full Text] [Related]
11. Toll-like receptors in the spotlight. O'Neill LA; Brown Z; Ward SG Nat Immunol; 2003 Apr; 4(4):299. PubMed ID: 12660723 [No Abstract] [Full Text] [Related]
14. Expression of toll-like receptor 4 on dendritic cells is significant for anticancer effect of dendritic cell-based immunotherapy in combination with an active component of OK-432, a streptococcal preparation. Okamoto M; Furuichi S; Nishioka Y; Oshikawa T; Tano T; Ahmed SU; Takeda K; Akira S; Ryoma Y; Moriya Y; Saito M; Sone S; Sato M Cancer Res; 2004 Aug; 64(15):5461-70. PubMed ID: 15289356 [TBL] [Abstract][Full Text] [Related]
15. [Role of toll-like receptor in innate immunity]. Takeda K; Akira S Tanpakushitsu Kakusan Koso; 2002 Dec; 47(16 Suppl):2097-102. PubMed ID: 12518420 [No Abstract] [Full Text] [Related]
16. Toll signaling: the TIReless quest for specificity. Imler JL; Hoffmann JA Nat Immunol; 2003 Feb; 4(2):105-6. PubMed ID: 12555093 [No Abstract] [Full Text] [Related]
17. Biology of Toll receptors: lessons from insects and mammals. Imler JL; Zheng L J Leukoc Biol; 2004 Jan; 75(1):18-26. PubMed ID: 12960276 [TBL] [Abstract][Full Text] [Related]